Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hypoglycemia has been associated with an increased risk of cardiovascular (CV) events and all-cause mortality. This study assessed whether, in a nationally representative population, there is an association between hypoglycemia, the risk of CV events, and all-cause mortality among insulin-treated people with type 1 diabetes or type 2 diabetes. RESEARCH DESIGN AND METHODS: This retrospective cohort study used data from the Clinical Practice Research Datalink database and included all insulin-treated patients (≥30 years of age) with a diagnosis of diabetes. RESULTS: In patients who experienced hypoglycemia, hazard ratios (HRs) for CV events in people with type 1 diabetes were 1.51 (95% CI 0.83, 2.75; P = ns) and 1.61 (1.17, 2.22), respectively, for those with and without a history of CV disease (CVD) before the index date. In people with type 2 diabetes, the HRs for patients with and without a history of CVD were 1.60 (1.21, 2.12) and 1.49 (1.23, 1.82), respectively. For all-cause mortality, HRs in people with type 1 diabetes were 1.98 (1.25, 3.17), and 2.03 (1.66, 2.47), respectively, for those with and without a history of CVD. Among people with type 2 diabetes, HRs were 1.74 (1.39, 2.18) and 2.48 (2.21, 2.79), respectively, for those with and without a history of CVD. The median time (interquartile range) from first hypoglycemia event to first CV event was 1.5 years (0.5, 3.5 years) and 1.5 years (0.5, 3.0 years), respectively, for people with type 1 and type 2 diabetes. CONCLUSIONS: Hypoglycemia is associated with an increased risk of CV events and all-cause mortality in insulin-treated patients with diabetes. The relationship between hypoglycemia and CV outcomes and mortality exists over a long period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CVD mortality accounts for 30-44% of all deaths in patients with T1DM.[780][781][782][783][784]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“People with T1DM face a three-fold increase in mortality compared with the general population”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“which translates into an 11-year reduction in life expectancy”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“multiple studies have shown a strong relationship between hypoglycemia (severe or not severe) and cardiovascular events and mortality”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [200]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Since the ACCORD and VADT results were published, attempts have been made to assess whether a relationship exists between hypoglycemia and CV risk or mortality, but only recently has a consensus begun to emerge suggesting that there is a link between the two (6,8,9).”
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Amiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Self-citationEffects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
“On the other hand, SGLT2 inhibitors may not induce the deleterious effects described for other antihyperglycemic drugs that can offset the benefits of improved blood glucose control on the cardiovascular system, including an increase in body weight and, particularly, an increase in hypoglycemic episodes (35).”
BackgroundPapachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
“There is evidence that hypoglycemia may unfavorably influence cardiovascular risk in patients with diabetes [175], and this is one possible explanation for the lack of CVD prevention in trials of intensive glycemic control.”
BackgroundAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Development of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
“An important clinical aspect of developing a glucoselowering drug is the risk of hypoglycaemia, since episodes of hypoglycaemia can impair cardioprotective effects, in part due to activation of the sympathetic nervous system [17].”
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.015 · Cited by 239
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
Vistisen, D., Andersen, G. S., Hansen, C. S., Hulman, A., Henriksen, J. E., Bech-Nielsen, H., & Jørgensen, M. E. (2016) · Circulation · doi:10.1161/circulationaha.115.018844 · Cited by 229
“1058 Patients with type 1 diabetes mellitus (T1D) have an almost 3-fold increased mortality risk in comparison with the general population.(1,2) Cardiovascular disease (CVD) is the main cause of this excess mortality(3) with CVD events happening more than a decade earlier.”
BackgroundLee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226
Minimizing Hypoglycemia in Diabetes
International Hypoglycaemia Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0279 · Cited by 209
“Hypoglycemia is associated with an increased risk of cardiovascular events and all-cause mortality in insulintreated patients with type 1 and type 2 diabetes (58).”
Backgroundvon Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
SGLT2 inhibition and kidney protection
Nespoux, J., & Vallon, V. (2018) · Clinical Science · doi:10.1042/cs20171298 · Cited by 172
“This is relevant since episodes of hypoglycemia can impair cardioprotective effects [38].”
Backgroundon behalf of the DEVOTE Study Group, Zinman, B., Marso, S. P., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Lange, M., Brown-Frandsen, K., Moses, A., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4423-z · Cited by 169
Cardiovascular Risk in Type 1 Diabetes Mellitus
Schofield, J., Ho, J., & Soran, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0612-8 · Cited by 150
Bally, L., Thabit, H., Kojzar, H., Mader, J. K., Qerimi-Hyseni, J., Hartnell, S., Tauschmann, M., Allen, J. M., Wilinska, M. E., Pieber, T. R., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30001-3 · Cited by 150
Glucose transporters in the kidney in health and disease
Vallon, V. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02361-w · Cited by 161
“Nevertheless, the intact metabolic counterregulation is potentially relevant for cardiovascular outcome, since episodes of hypoglycemia impair the cardioprotective effects of anti-hyperglycemic therapy [80].”
BackgroundLee, Y.-B., Han, K., Kim, B., Lee, S.-E., Jun, J. E., Ahn, J., Kim, G., Jin, S.-M., & Kim, J. H. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0953-7 · Cited by 131
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19099 · Cited by 141
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
The role of patient education in the prevention and management of type 2 diabetes: an overview
Coppola, A., Sasso, L., Bagnasco, A., Giustina, A., & Gazzaruso, C. (2015) · Endocrine · doi:10.1007/s12020-015-0775-7 · Cited by 171
“For example, hypoglycemia is an important problem in the management of diabetes not only for quality of life, social, and economic costs [44], but also for the implications in terms of mortality and cardiovascular risk [44, 45].”
BackgroundHypoglycemia and Cardiovascular Risk: Is There a Major Link?
Hanefeld, M., Frier, B. M., & Pistrosch, F. (2016) · Diabetes Care · doi:10.2337/dcs15-3014 · Cited by 121
“one episode of severe hypoglycemia (9).”
Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
Ajjan, R., Slattery, D., & Wright, E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0870-x · Cited by 120
O’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113
Vergès, B. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.001 · Cited by 112
Wu, N., Bredin, S. S. D., Guan, Y., Dickinson, K., Kim, D. D., Chua, Z., Kaufman, K., & Warburton, D. E. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020253 · Cited by 110
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Zinman, B., Marso, S. P., Christiansen, E., Calanna, S., Rasmussen, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-2677 · Cited by 108
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 138
Davidson, M. D., Ballinger, K. R., & Khetani, S. R. (2016) · Scientific Reports · doi:10.1038/srep28178 · Cited by 107
Sherr, J. L., Laffel, L. M., Liu, J., Wolf, W., Bispham, J., Chapman, K. S., Finan, D., Titievsky, L., Liu, T., Hagan, K., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1765 · Cited by 99
How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?
Ajjan, R. A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0021 · Cited by 97
Seidu, S., Kunutsor, S. K., Topsever, P., Hambling, C. E., Cos, F. X., & Khunti, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13724 · Cited by 97
Self-citationFlash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
Gomez-Peralta, F., Dunn, T., Landuyt, K., Xu, Y., & Merino-Torres, J. F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001052 · Cited by 94
Proinflammatory effects of hypoglycemia in humans with or without diabetes
Ratter, J. M., Rooijackers, H. M. M., Tack, C. J., Hijmans, A. G. M., Netea, M. G., de Galan, B. E., & Stienstra, R. (2017) · Diabetes · doi:10.2337/db16-1091 · Cited by 94
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 93
“When considering a drug to lower blood glucose levels in T1DM and T2DM, one must consider the risk of hypoglycaemia, since episodes of hypoglycaemia can impair cardioprotective effects, an effect partially caused by activation of the sympathetic nervous system.(74) Fortunately, the risk of hypoglycaemia during treatme…”
BackgroundDennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., Pearson, E. R., Hattersley, A. T., Shields, B. M., Jones, A. G., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13687 · Cited by 85
“19 Because of the low number of hypoglycaemia events captured in primary care we grouped data into biannual categories representing four distinct periods (2010-2011, 2012-2013, 2014-2015, 2016-2017).”
Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans
Iqbal, A., Prince, L. R., Novodvorský, P., Bernjak, A., Thomas, M. R., Birch, L., Lambert, D., Kay, L. J., Wright, F., Macdonald, I. A., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01168 · Cited by 97
Yun, J., Park, Y., Han, K., Cha, S., Ahn, Y., & Ko, S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0909-y · Cited by 99
Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study
Zaccardi, F., Davies, M. J., Dhalwani, N. N., Webb, D. R., Housley, G., Shaw, D. E., Hatton, J. W., & Khunti, K. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30091-2 · Cited by 80
Self-citationThe Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Fattah, H., & Vallon, V. (2018) · Drugs · doi:10.1007/s40265-018-0901-y · Cited by 75
“term enhance cardiovascular risk in these patients [13].”
Lawson, C. A., Jones, P. W., Teece, L., Dunbar, S. B., Seferovic, P. M., Khunti, K., Mamas, M. A., & Kadam, U. T. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.08.020 · Cited by 79
Self-citationNatali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 75
Mattishent, K., & Loke, Y. K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.571568 · Cited by 69
“Association Between Hypoglycemia and Macro- and Microvascular Disease and Cardiovascular Death 19 studies confirmed a significant association between hypoglycemia and macrovascular complications (3, 4, 10, 11, 14, 16, 17, 18, 20, 23, 26, 28, 34, 36, 38, 40, 43, 45, 46).”
BackgroundAssociation of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus
Mehta, H. B., Mehta, V., & Goodwin, J. S. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw217 · Cited by 68
“The primary independent variable, hypoglycemia, was defined based on a previously defined algorithm for the CPRD data (17).”
van Meijel, L. A., de Vegt, F., Abbink, E. J., Rutters, F., Schram, M. T., van der Klauw, M. M., Wolffenbuttel, B. H. R., Siegelaar, S., DeVries, J. H., Sijbrands, E. J. G., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000935 · Cited by 68
Goto, A., Goto, M., Terauchi, Y., Yamaguchi, N., & Noda, M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002875 · Cited by 67
“…Europe, Russia, Asia, Australia4 65 64 6.2 (median) 12 537 5.4 (mean)† 3.8 Bedenis et al. (2014)*, Scotland5 51 68 4 (mean) 1.066 8.1 (mean) 8.2 Khunti et al. (2015)*, UK29 56 63 4.8 (median) 10 422 NA 14.0 Goto et al. (2016)*, Japan 70 54 2.3 (mean) 58 223 3.2 (mean) 0.2 NA indicates not…”
BackgroundInfluentialBasics and use of continuous glucose monitoring (CGM) in diabetes therapy
Freckmann, G. (2020) · Journal of Laboratory Medicine · doi:10.1515/labmed-2019-0189 · Cited by 87
“Severe hypoglycemia can lead to coma or death and has been linked to increased mortality [1, 5].”
BackgroundKatakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Torimoto, K., Umayahara, Y., Kaneto, H., Osonoi, T., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01079-4 · Cited by 68
Lu, C.-L., Shen, H.-N., Hu, S. C., Wang, J.-D., & Li, C.-Y. (2016) · Diabetes Care · doi:10.2337/dc15-2418 · Cited by 66
“(6), who used administrative health data to investigate episodes of severe hypoglycemia that occurred any time during the 5-year follow-up period.”
BackgroundResultVergès, B. L. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.005 · Cited by 80
Hambling, C. E., Seidu, S. I., Davies, M. J., & Khunti, K. (2017) · Diabetic Medicine · doi:10.1111/dme.13380 · Cited by 62
Self-citationWang, D., Hu, X., Lee, S. H., Chen, F., Jiang, K., Tu, Z., Liu, Z., Du, J., Wang, L., Yin, C., et al. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.005 · Cited by 60
“Our data presented here pose a therapeutic dilemma as well as its possible solution: if insulin therapy is potentially detrimental to cardiac outcomes, as data from our group and others suggest (32,44), then how can we approach T2DM patients with hyperglycemia not controlled by standard oral therapy? Although 1 analys…”
ResultBode, B. W., & Garg, S. K. (2015) · Endocrine Practice · doi:10.4158/ep15869.ra · Cited by 56
Elwen, F. R., Huskinson, A., Clapham, L., Bottomley, M. J., Heller, S. R., James, C., Abbas, A., Baxter, P., & Ajjan, R. A. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000094 · Cited by 55
“were older than 30 years.(27) In contrast to our study, however, the authors failed to assess mortality in those who were not on insulin treatment.”
ResultKoliaki, C. C., Tentolouris, A., Eleftheriadou, I., Melidonis, A. J., Dimitriadis, G., & Tentolouris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072288 · Cited by 62
SGLT1: A Potential Drug Target for Cardiovascular Disease
Zhao, M., Li, N., & Zhou, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s418321 · Cited by 62
“When it comes to glucose-lowering drugs, it is important to consider whether there is a risk of hypoglycemia, which can activate sympathetic nerves and thus damage the heart.(48) One of the advantages of SGLT2 inhibitors is the lower risk of hypoglycemia during their treatment.”
BackgroundLaManna, J., Litchman, M. L., Dickinson, J. K., Todd, A., Julius, M. M., Whitehouse, C. R., Hyer, S., & Kavookjian, J. (2019) · The Diabetes Educator · doi:10.1177/0145721719855931 · Cited by 50
Liberating A1C goals in older adults may not protect against the risk of hypoglycemia
Munshi, M. N., Slyne, C., Segal, A. R., Saul, N., Lyons, C., & Weinger, K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.014 · Cited by 57
Gordon, J. P., McEwan, P. C., IDRIS, I. R., Evans, M., & Puelles, J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000512 · Cited by 51
Mertens, J., Block, C. E. M. D., Spinhoven, M. J., Driessen, A. L. C., Francque, S., & Kwanten, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768576 · Cited by 54
Saremi, A., Bahn, G. D., & Reaven, P. D. (2016) · Diabetes Care · doi:10.2337/dc15-2107 · Cited by 44
Understanding the impact of hypoglycemia on the cardiovascular system
Davis, I., Ahmadizadeh, I., Randell, J., Younk, L. M., & Davis, S. N. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1275960 · Cited by 50
SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 49
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
β Cell Replacement Therapy: The Next 10 Years
Schuetz, C., Anazawa, T., Cross, S. E., Labriola, L., Meier, R. P. H., Redfield, R. R., Scholz, H., Stock, P. G., & Zammit, N. W. (2017) · Transplantation · doi:10.1097/tp.0000000000001937 · Cited by 49
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Stuart, K., Adderley, N. J., Marshall, T. P., Rayman, G. A., Sitch, A. J., Manley, S. E., Ghosh, S., Toulis, K. A., & Nirantharakumar, K. (2017) · Diabetic Medicine · doi:10.1111/dme.13409 · Cited by 45
Bromocriptine therapy: Review of mechanism of action, safety and tolerability
Naz, F., Malik, A. R., Riaz, M., Mahmood, Q., Mehmood, M. H., Rasool, G., Mahmood, Z., & Abbas, M. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13678 · Cited by 54
Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes
McCoy, R. G., Herrin, J., Lipska, K. J., & Shah, N. D. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.007 · Cited by 40
“Principal diagnoses were identified using the first/primary discharge diagnosis ICD-9- CM code from the hospitalization claim and categorized as hypoglycemic or hyperglycemic based on validated algorithms: (1) Hypoglycemia: ICD-9-CM 251.”
MethodLega, I. C., Campitelli, M. A., Austin, P. C., Na, Y., Zahedi, A., Leung, F., Yu, C., Bronskill, S. E., Rochon, P. A., & Lipscombe, L. L. (2021) · Diabetologia · doi:10.1007/s00125-020-05370-7 · Cited by 40
Determinants of mortality in patients with type 2 diabetes: a review
Engelmann, J., Manuwald, U., Rubach, C., Kügler, J., Birkenfeld, A. L., Hanefeld, M., & Rothe, U. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9349-0 · Cited by 44
“Sulfonylurea treatment is associated with an increased all-cause or cardiovascular mortality due to the high risk for hypoglycemia [32, 99] and therefore, this treatment should not”
BackgroundQi, X., Xu, J., Chen, G., Liu, H., Liu, J., Wang, J., Zhang, X., Hao, Y., Wu, Q., & Jiao, M. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01881-y · Cited by 48
“However, it might be dangerous to multi-vulnerable patients because it might result in hypoglycemia, causing dysfunctional osmolality and a range of consequences [62], including death [63].”
BackgroundEchouffo-Tcheugui, J. B., Daya, N., Lee, A. K., Tang, O., Ndumele, C. E., Windham, B. G., Shah, A. M., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-0552 · Cited by 38
Meta-analysis: Association between hypoglycaemia and serious adverse events in older patients
Mattishent, K., & Loke, Y. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.018 · Cited by 41
“death among insulin-treated people with diabetes (Khunti et al., 2015).”
BackgroundResultInfluentialNetwork analysis of depressive and anxiety symptoms in older Chinese adults with diabetes mellitus
Zhang, Y., Cui, Y., Li, Y., Lü, H., Huang, H., Sui, J., Guo, Z., & Miao, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1328857 · Cited by 46
Divilly, P., Martine‐Edith, G., Zaremba, N., Søholm, U., MAHMOUDI, Z., Cigler, M., Ali, N., Abbink, E. J., Brøsen, J. M. B., de Galan, B. E., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2332 · Cited by 51
The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk
Sandler, C. N., & McDonnell, M. E. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s1.02 · Cited by 41
Paul, S. K., Shaw, J. E., Montvida, O., & Klein, K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12761 · Cited by 39
“Asian 639 (5) 891 (3) 603 (2) 267 (1) 216 (1)”
Self-citationVallon, V. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae060 · Cited by 46
Conget, I., Castañeda, J., Petrovski, G., Guerci, B., Racault, A.-S., Reznik, Y., Cohen, O., Runzis, S., de Portu, S., Aronson, R., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0159 · Cited by 38
Yu, M., Xie, R., Zhang, Y., Liang, H., Hou, L., Yu, C., Zhang, J., Dong, Z., Tian, Y., Bi, Y., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy027 · Cited by 36
“These results indicated that cells could be activated or injured under these conditions that occur frequently during DKD [37], and suggesting that in clinical practice, a gradual correction of blood glucose in patients with hypoglycemia may be preferred to a more rapid correction resulting in hyperglycemia.”
BackgroundExplaining the increased mortality in type 1 diabetes
Mameli, C., Mazzantini, S., Nasr, M. B., Fiorina, P., Scaramuzza, A. E., & Zuccotti, G. V. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.889 · Cited by 42
Christensen, M. B., Gæde, P., Hommel, E. E., Gotfredsen, A., & Nørgaard, K. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.02.002 · Cited by 34
Zaccardi, F., Ling, S., Lawson, C. A., Davies, M. J., & Khunti, K. (2020) · Diabetologia · doi:10.1007/s00125-020-05223-3 · Cited by 38
Self-citationLing, S., Zaccardi, F., Lawson, C., Seidu, S., Davies, M. J., & Khunti, K. (2021) · Diabetes Care · doi:10.2337/dc20-0876 · Cited by 46
Self-citationBenhamou, P., Adenis, A., Tourki, Y., Pou, S., Madrolle, S., Franc, S., Kariyawasam, D., Beltrand, J., Klonoff, D. C., & Charpentier, G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221128565 · Cited by 33
Vetrone, L. M., Zaccardi, F., Webb, D. R., Seidu, S., Gholap, N. N., Pitocco, D., Davies, M. J., & Khunti, K. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1253-5 · Cited by 36
Self-citationGregg, E. W., Patorno, E., Karter, A. J., Mehta, R., Huang, E. S., White, M., Patel, C. J., McElvaine, A. T., Cefalu, W. T., Selby, J. V., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1438 · Cited by 40
Self-citationAjjan, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16098 · Cited by 40
On behalf of the UTOPIA study investigators, Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Umayahara, Y., Kaneto, H., Osonoi, T., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0292-1 · Cited by 32
“Since the mode of action of SGLT2 inhibitors is independent of insulin secretion, these agents are associated with a low risk of hypoglycemia, which is linked to an increased of CV events [7, 8, 16].”
BackgroundNishioka, Y., Okada, S., Noda, T., Myojin, T., Kubo, S., Ohtera, S., Kato, G., Kuroda, T., Ishii, H., & Imamura, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13153 · Cited by 28
“11 a-Glucosidase inhibitors 1,940,735 (25) 14,591 (30) 1,926,144 (25) 0.”
Epigenetic role of N6-methyladenosine (m6A) RNA methylation in the cardiovascular system
Zhao, K., Yang, C., Li, P., Sun, W. Y., & Kong, X. (2020) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900680 · Cited by 33
Takeishi, S., Mori, A., Hachiya, H., Yumura, T., Ito, S., Shibuya, T., Hayashi, S., Fushimi, N., Ohashi, N., & Kawai, H. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12436 · Cited by 36
Wei, W., Zhao, S., Fu, S.-L., Lan, Y., Mao, H., Tan, Q., Xu, P., & Yang, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00536 · Cited by 32
“Also, there were many observational studies, with inconsistent results of the association between hypoglycemia and MACE outcomes (7, 15).”
ResultMuneer, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_534 · Cited by 28
Devices for continuous monitoring of glucose: update in technology
Gómez, A. M., Carrillo, D. C. H., & Múñoz, Ó. (2017) · Medical Devices Evidence and Research · doi:10.2147/mder.s110121 · Cited by 35
Metadata
- Authors
- Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K.
- Affiliations
- University of Leicester (GB)
- Imperial College London (GB)
- Novo Nordisk (Denmark) (DK)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Khunti, Kamlesh
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-09
- Volume
- 38
- Issue
- 2
- Pages
- 316-322
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128592897
- Cited by
- 356
- References
- 32
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 26 · 2023: 34 · 2022: 26 · 2021: 39 · 2020: 33 · 2019: 38 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 20
- FWCI
- 25.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypoglycemia, cardiovascular disease, all-cause mortality, type 1 diabetes, type 2 diabetes, insulin-treated diabetes, cardiovascular events, mortality risk
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, England, Epidemiologic Methods, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.